Local application of statins in the treatment of experimental periodontal disease in rats

Santos, Bianca Fernanda Espósito; Souza, Eduardo Quintão Manhanini; Brigagão, Maı́sa Ribeiro Pereira Lima; Lima, Daniela Coêlho de; Fernandes, Leandro Araújo

doi:10.1590/1678-77572016-0149

Cited by 12 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most statins have been reported to potently inhibit the expression of MMP-1, MMP-8, and MMP-9 upregulated by LPS as demonstrated for simvastatin in mononuclear cells in vitro [ 56 ]. Moreover, in vivo , a decrease of MMP-1, MMP-2, MMP-8, and MMP-9 was observed by the use of statins [ 31 , 57 – 59 ]. Thus, statins prevent periodontal tissue and alveolar bone destruction by inhibiting the release of MMPs.…”

Section: Resultsmentioning

confidence: 99%

Contribution of Statins towards Periodontal Treatment: A Review

Petit

Batool

Bugueno

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

The pleiotropic effects of statins have been evaluated to assess their potential benefit in the treatment of various inflammatory and immune-mediated diseases including periodontitis. Herein, the adjunctive use of statins in periodontal therapy in vitro, in vivo, and in clinical trials was reviewed. Statins act through several pathways to modulate inflammation, immune response, bone metabolism, and bacterial clearance. They control periodontal inflammation through inhibition of proinflammatory cytokines and promotion of anti-inflammatory and/or proresolution molecule release, mainly, through the ERK, MAPK, PI3-Akt, and NF-κB pathways. Moreover, they are able to modulate the host response activated by bacterial challenge, to prevent inflammation-mediated bone resorption and to promote bone formation. Furthermore, they reduce bacterial growth, disrupt bacterial membrane stability, and increase bacterial clearance, thus averting the exacerbation of infection. Local statin delivery as adjunct to both nonsurgical and surgical periodontal therapies results in better periodontal treatment outcomes compared to systemic delivery. Moreover, combination of statin therapy with other regenerative agents improves periodontal healing response. Therefore, statins could be proposed as a potential adjuvant to periodontal therapy. However, optimization of the combination of their dose, type, and carrier could be instrumental in achieving the best treatment response.

show abstract

Section: Resultsmentioning

confidence: 99%

Contribution of Statins towards Periodontal Treatment: A Review

Petit

Batool

Bugueno

et al. 2019

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Taurolidine gel was shown to have antimicrobial effects and useful for periodontal therapy [19]. Other experimental drugs, such as chlorhexidine, tetracycline/hydrochloride, locale application of statins, were used as adjunctive treatments to scaling and root planning and were found to have antimicrobial, anti-inflammatory, and modulated bone remodeling process in a rat model of PD [20][21][22][23]. Other medications for osteoporosis, such as bisphosphonates (BPs), are used to treat bone loss resulting from periodontitis.…”

Section: Discussionmentioning

confidence: 99%

A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

Jiang

Liu

et al. 2020

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Currently, there are no effective medications to reverse periodontal disease (PD)-induced bone loss. The objective of this study was to test a new anabolic compound, LLP2A-Ale, or with the combination treatment of mesenchymal stromal cell (MSC), in the treatment of bone loss secondary to PD. Methods PD was induced in mice by placing a ligature around the second right molar. At one week after disease induction, the mice were treated with placebo, LLP2A-Ale, MSCs, or combination of LLP2A-Ale + MSCs, and euthanized at week 4. Results We found that PD induced alveolar bone loss that was associated with reduced bone formation. LLP2A-Ale alone or in combination with MSCs sustained alveolar bone formation and reversed alveolar bone loss. Additionally, PD alone caused systemic inflammation and increased the circulating levels of G-CSF, IP-10, MIP-1a, and MIP2, which were suppressed by LLP2A-Ale +/− MSCs. LLP2A-Ale +/− MSCs increased bone formation at the peripheral skeletal site (distal femur), which was otherwise suppressed by PD. Conclusion Our findings indicated that LLP2A-Ale treatment rescued alveolar bone loss caused by PD, primarily by increasing bone formation. LLP2A-Ale also attenuated the circulating levels of a series of inflammatory cytokines and reversed the PD-induced suppression of systemic bone formation.

show abstract

“…Taurolidine gel was shown to have antimicrobial effects and useful for periodontal therapy [19]. Other experimental drugs, such as chlorhexidine, tetracycline/hydrochloride, locale application of statins, were used as adjunctive treatments to scaling and root planning and were found to have antimicrobial, anti-in ammatory, and modulated bone remodeling process in a rat model of PD [20][21][22][23].…”

Section: Discussionmentioning

confidence: 99%

A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

Jiang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Currently, there are no effective medications that reverse periodontal disease (PD)-induced bone loss. The objective of this study was to test a new anabolic compound, LLP2A-Ale, or with the combination treatment of mesenchymal stromal cell (MSC), in the treatment of bone loss secondary to PD. Methods. PD was induced in mice by placing a ligature around the second right molar. At one week after disease induction, the mice were treated with placebo, LLP2A-Ale, MSCs, or combination of LLP2A-Ale + MSCs, and euthanized at week 4. Results. We found that PD induced alveolar bone loss that was associated with reduced bone formation. LLP2A alone and in combination with MSCs sustained alveolar bone formation and reversed alveolar bone loss. Additionally, PD alone caused systemic inflammation and increased the circulating levels of G-CSF, IP-10, MIP-1a, and MIP2, which were suppressed by LLP2A-Ale +/- MSCs. LLP2A-Ale +/- MSCs increased bone formation at the peripheral skeletal site (distal femur), which was otherwise suppressed by PD. Conclusion. Our findings indicated that LLP2A-Ale treatment rescued alveolar bone loss caused by PD, primarily by increasing bone formation. LLP2A-Ale also attenuated the circulating levels of a series of inflammatory cytokines and reversed the PD-induced suppression of systemic bone formation.

show abstract

Local application of statins in the treatment of experimental periodontal disease in rats

Cited by 12 publications

References 31 publications

Contribution of Statins towards Periodontal Treatment: A Review

Contribution of Statins towards Periodontal Treatment: A Review

A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation

Contact Info

Product

Resources

About